Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) has provided an update.
On March 2, 2026, Zymeworks reported that 2025 revenue rose 39% year over year to $106.0 million and its net loss narrowed by 34% to $81.1 million, ending the year with $270.6 million in cash, cash equivalents and marketable securities. The company has used $62.5 million for share repurchases and secured a $250.0 million non-recourse royalty-backed note from Royalty Pharma, pledging only 30% of Ziihera royalties, to fund buybacks, extend its cash runway beyond 2028 and support potential acquisitions, while preserving most future royalty cash flows.
Zymeworks outlined 2026 R&D priorities, including continued Phase 1 studies for ZW191 and ZW251, planned IND submissions for multispecific programs ZW209 and ZW1528, and a strategy to advance next-generation multispecific antibody and engineered-cytokine platforms with help from partnerships. On the partnered side, positive Phase 3 HERIZON-GEA-01 data reported in November 2025 support Ziihera as a potential new first-line standard of care in HER2-positive gastroesophageal adenocarcinoma, triggering a planned U.S. regulatory filing in early 2026, approvals in biliary tract cancer in Canada and the U.K., and positioning Zymeworks to earn up to $440.0 million in GEA-related milestones plus additional payments tied to further indications and tiered global royalties from partner Jazz.
The most recent analyst rating on (ZYME) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
The score is held back mainly by weak profitability and negative operating cash flow, with additional pressure from bearish/oversold technical signals. Offsetting these, the latest earnings call was meaningfully constructive—highlighting milestone-driven revenue growth, promising clinical updates, and a multi-year cash runway—supporting a more neutral overall outcome.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a Vancouver-based biotechnology company that manages a portfolio of licensed healthcare assets while developing a pipeline of novel, multifunctional biotherapeutics. Its business model combines royalty-generating partnered drugs, such as the HER2-targeted therapy Ziihera (zanidatamab-hrii), with wholly owned R&D programs focused on multispecific antibodies and engineered cytokines in oncology.
Average Trading Volume: 704,413
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.76B
See more data about ZYME stock on TipRanks’ Stock Analysis page.